George Bakris to Metabolic Syndrome
This is a "connection" page, showing publications George Bakris has written about Metabolic Syndrome.
Connection Strength
3.123
-
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6.
Score: 0.367
-
The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med. 2010 Jul; 123(7 Suppl 1):S21-6.
Score: 0.334
-
Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14.
Score: 0.327
-
Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab. 2009 Mar; 11(3):177-87.
Score: 0.290
-
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr. 2008; 3(1):18-25.
Score: 0.281
-
Current perspectives on hypertension and metabolic syndrome. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S3-5.
Score: 0.270
-
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12):2592-7.
Score: 0.261
-
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep. 2006 Jun; 6(3):219-24.
Score: 0.252
-
Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr. 2006; 1(1):58-65.
Score: 0.245
-
Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach. J Cardiometab Syndr. 2006; 1(5):334-42; quiz 343.
Score: 0.245
-
Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. J Cardiometab Syndr. 2008; 3(2):119-25.
Score: 0.070
-
The cardiometabolic syndrome and calcium channel blocker combination drugs. J Cardiometab Syndr. 2007; 2(3):207-12.
Score: 0.066
-
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
Score: 0.063
-
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
Score: 0.019
-
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007; 16(2):72-9.
Score: 0.016
-
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
Score: 0.015